A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

Recruiting

Phase 2

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive DisorderA Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

Sponsor:

Sirtsei Pharmaceuticals, Inc.

Code:

NCT06254612

Conditions

Major Depressive Disorder

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

SP-624

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Sirtsei Pharmaceuticals, Inc. on 2025-03-25.